Skip to main content
ERC
News
Participate
Patients
Doctors
Investors
Products
Gliovac/ERC1671
Media
News
Publications
About
Executive board
Scientific board
Milestone achievements
Contact
Error message
Notice
: Undefined index: HTTP_ACCEPT_LANGUAGE in
_konnu_footer()
(line
106
of
/home/erc/web/erc-immunotherapy.com/public_html/sites/all/modules/konnu/konnu.module
).
News
Publications
31
Dec
2018
CEO’s statement for 2018
31
Aug
2018
12 month progress report 31/08/2017-31/09/2018
ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
08
Jul
2016
New production site in the Netherlands
ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
15
May
2016
Approval for open phase II study
ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination
with Gliovac/ERC1671
vs
standard treatments
...
29
Mar
2016
Interest to use our technology for other cancers
Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our
cookies information
for more details.
Close
